Chronic disease management is a $4 trillion market built on systems fundamentally ill-equipped to handle the realities of long-term illness.
The care patients experience is often fragmented and episodic. After a lengthy wait even to get an initial diagnosis, patients are offered 15 minute appointments every few months. This is followed by months of silence, where flare-ups, side effects and new symptoms are navigated completely alone.
When something does go wrong, the only solution is to re-join the queue for another brief slot with whichever specialist happens to be available. Each new appointment effectively starts from scratch.
This is a structural problem. Care for long-term conditions is built to handle single episodes – a diagnosis, a check-up, a flare-up – rather than the months of ongoing management in between. The best specialists are oversubscribed and cannot scale their services. Genuine multidisciplinary care is relegated to academic centres, as only they have the volume to justify it.
Resolyst is built to fill in those gaps. It provides the clinical workflow layer that runs between appointments and across specialisms. The platform sits underneath a specialist’s existing practice, giving them two tools: a continuous care platform where patients log symptoms and are monitored between visits, and a specialist portal where the doctor oversees the whole caseload.
Underneath both, agents handle intake, monitoring and escalation, routing routine work to a network of nurses and allied health professionals, while anything requiring clinical judgement goes to the consultant. The rare, most complex cases escalate further, to an international panel of leading specialists.
Every recommendation is checked by a clinician before it reaches the patient. The specialist stays in oversight of their patients throughout, now with a far larger team working around them.
Why the data gap matters as much as the care gap
The same fragmentation that leaves patients unsupported between visits also starves an entire industry of vital data. Pharma companies and clinical researchers need clean, structured, longitudinal datasets to run better trials and understand how a disease actually progresses over time.
Today’s visit-by-visit model can’t produce that. A blood test at a GP, a specialist note in a private clinic, and a prescription record in a hospital system don’t equate to a cohesive medical history.
This is where Resolyst’s model compounds, rather than just fixes a workflow problem. Every structured interaction inside a continuous care programme becomes, as a by-product, part of a research-grade dataset, turning individual specialist practices into research nodes that life sciences partners can license data from or recruit trial-ready patients through.
Over time, this becomes the substrate for pathway-specific clinical intelligence models that can keep refining best practice as more patients move through the system.
Why we backed Molly
Molly is uniquely well-equipped to build this solution. A medical degree from Oxford, healthcare strategy work at McKinsey, working as an operator at a VC backed startup, and years spent on the other side of the table evaluating health-tech companies as an investor – she’s seen this exact problem as a consultant, operator and an investor.
There’s a real opportunity here, both to generate the dataset the rest of the industry will need to build on, and to tangibly improve patients’ quality of life. We’re glad to be backing Molly and the Resolyst team from day one.
Find out more about Resolyst here.